The negative feedback loop on the hepatocyte-TLR4-IL-17A axis could be a potential anti-carcinogenetic mechanism for FGF21 to prevent NASH-HCC transition. Here, FGF21 is linked to metabolic dysfunction-associated steatohepatitis.